Shares of Enanta Pharmaceuticals (ENTA) are down by over 55% in the past month, trading at around $8.
This clinical-stage biotechnology company focused on developing drugs for virology and immunology indications has a clinical trial to watch next month (December).
The company's lead drug candidate is Zelicapavir, also known as EDP 938, which is being evaluated in two phase II clinical trials in high-risk RSV pediatric and adult populations, dubbed RSVPEDs and RSVHR.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.